Generate co-founder Molly Gibson and CEO Mike Nally

Flag­ship's ma­chine learn­ing start­up Gen­er­ate bags $370M in lat­est round with plans for a big hir­ing spree

As the fu­ture of ma­chine learn­ing and AI promis­es to make ma­jor break­throughs in drug de­vel­op­ment, a suite of star­tups is look­ing to scale their own com­pet­ing ro­bot brain trusts. An am­bi­tious start­up out of Flag­ship Pi­o­neer­ing’s in­cu­ba­tor un­cloaked last year with its own spin in that arms race — and now it’s primed and ready for a ma­jor ex­pan­sion in the com­ing years.

Gen­er­ate Bio­med­i­cines has closed a gi­ant $370 mil­lion Se­ries B from found­ing in­vestor Flag­ship as well as Alas­ka Per­ma­nent Fund, Al­ti­tude Life Sci­ence Ven­tures, ARCH Ven­ture Part­ners, and funds and ac­counts ad­vised by T. Rowe Price As­so­ciates, the com­pa­ny said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.